Surgery Partners’ planned sale of Mountain View Hospital and Idaho Falls Community Hospital would reshape its balance sheet and income statement sharply if the deal had closed on June 30, 2026.
The company said the transaction would bring in about $796.6 million in cash consideration, before closing cash and debt, transaction expenses and other adjustments. After estimated closing cash and indebtedness of $219.7 million and net working capital adjustments of $9.6 million, net cash consideration at closing was estimated at $586.5 million.
On a pro forma basis, cash and cash equivalents would have jumped to $708.8 million from $216.7 million, an increase of $492.1 million. Total current assets would have risen to $1.42 billion from $1.13 billion, while total assets would have declined to $7.41 billion from $8.05 billion as the divested businesses were removed.
Several asset lines would have been reduced materially. Accounts receivable would have fallen to $466.5 million from $616.6 million, inventories to $74.7 million from $98.8 million, property and equipment net to $838.5 million from $1.12 billion, and goodwill and intangible assets net to $4.65 billion from $5.24 billion.
On the liability side, total current liabilities would have dropped to $457.0 million from $578.5 million. Long-term debt, less current maturities, would have come down to $3.33 billion from $3.65 billion. Total liabilities would have decreased to $4.47 billion from $4.95 billion.
Equity would have been reshaped as well. Total Surgery Partners stockholders’ equity would have edged up to $1.69 billion from $1.67 billion, while non-controlling interests would have fallen to $1.25 billion from $1.43 billion. Total stockholders’ equity would have declined to $2.94 billion from $3.10 billion.
For the six months ended June 30, 2026, revenues would have fallen to $1.29 billion from $1.66 billion, a drop of $372.0 million. Cost of revenues would have declined to $1.00 billion from $1.31 billion. Operating income would have fallen to $127.8 million from $167.9 million.
Net income attributable to Surgery Partners would have moved to a loss of $69.2 million from a loss of $50.9 million. Net loss per share would have widened to $0.54 from $0.40.
For full-year 2025, revenues would have come in at $2.59 billion versus $3.31 billion reported, down $722.6 million. Operating income would have been $314.8 million versus $389.5 million. Net income attributable to Surgery Partners would have been a loss of $108.2 million, compared with a loss of $77.9 million reported. Net loss per share would have widened to $0.85 from $0.61.
Interest expense, net, would have fallen to $127.7 million for the six-month period from $138.9 million reported, and to $247.3 million for 2025 from $272.6 million. Income before taxes would have slipped to $0.1 million for the first half of 2026 from $29.0 million, and to $67.5 million for 2025 from $116.9 million.
The company also said the deal would have produced an estimated gain on sale of $16.4 million, net of transaction costs, as of June 30, 2026. Today the company's shares have moved -2.88% to a price of $13.5295. For the full picture, make sure to review Surgery's 8-K report.
